Table 3.
Prognostic value of Mul1 expression on disease‐free survival by Cox proportional hazards model
| Variable | Disease‐free survival | |
|---|---|---|
| HR (95% CI) | P‐value | |
| Univariate analysis | ||
| Age, y (≥60 vs <60) | 1.820 (1.330‐2.491) | .000** |
| Gender (Male vs Female) | 1.058 (0.778‐1.440) | .719 |
| Tumor invasion (T1‐T2 vs T3‐T4) | 3.164 (2.339‐4.281) | .000** |
| Lymph node stage (N0 vs N1) | 3.386 (1.797‐6.377) | .000* |
| Pathological grade (G1‐G2 vs G3‐G4) | 2.612 (1.860‐3.669) | .000* |
| Clinical stage (S1‐S2 vs S3‐S4) | 3.853 (2.810‐5.283) | .000** |
| Distant metastasis (M0 vs M1) | 4.348 (3.187‐5.930) | .000** |
| Mul1 expression (low vs high) | 0.552 (0.402‐0.757) | .000** |
| Multivariate analysis | ||
| Mul1 expression (low vs high) | 0.663 (0.479‐0.918) | .013* |
| Tumor invasion (T1‐T2 vs T3‐T4) | 2.308 (1.672‐3.186) | .000** |
| Age, y (≥60 vs <60) | 1.605 (1.168‐2.208) | .004** |
| Pathological grade (G1‐G2 vs G3‐G4) | 1.765 (1.227‐2.540) | .002** |
Abbreviation: CI, confidence interval; HR, hazard ratio; Mul1, mitochondrial E3 ubiquitin ligase 1.
*P < .05; **P < .01.